Indeed, our data suggest that S3/physcion would possess multi-pronged anti-tumour activity in PCa by inhibiting oncogenic metabolism, including lipogenesis (i.e. activation of AMPK and suppression of ACC1 and mTOR); increasing levels of ROS, resulting in oxidative stress and lipid peroxidation; and finally, suppressing the levels and activity of AR, the primary oncogenic driver of this disease. Here, AR is linked to neoplasm.